Yüksel Ürün: Enzalutamide boosts OS and rPFS in mHSPC patients regardless of HSD3B1 genotype

Yüksel Ürün shared a paper by Nima Sharifi et al. on X:

“Enzalutamide boosts OS and rPFS in mHSPC patients regardless of HSD3B1 genotype. While clinical outcomes are similar across genotypes, the AP genotype shows higher post-progression mortality and TEAEs. Enzalutamide remains effective in mHSPC independent of HSD3B1 status.”

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES

Authors: Nima Sharifi, Arun A. Azad, Mona Patel, Jason W.D. Hearn, Michele Wozniak, Fabian Zohren, Jennifer Sugg, Gabriel P. Haas, Arnulf Stenzl, Andrew J. Armstrong

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.